Hostname: page-component-77c89778f8-fv566 Total loading time: 0 Render date: 2024-07-21T00:16:02.097Z Has data issue: false hasContentIssue false

P-115 - Clonidine Treatment of Nightmares in Ptsd

Published online by Cambridge University Press:  15 April 2020

A. Alao
Affiliation:
Psychiatry, SUNY Upstate Medical University, Syracuse, NY, USA
J. Selvarajah
Affiliation:
Psychiatry, SUNY Upstate Medical University, Syracuse, NY, USA

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Over 2 million US service members have now deployed to the Iraq and Afghanistan conflicts. Providers have consequently observed steep increases in mental health service use among these veterans. Dysregulation of the autonomic nervous system is thought to explain the physiological changes in patients with PTSD. This is the report of a patient whose nightmares were successfully treated with clonidine. Mr. F, a 48 years old man who developed PTSD symptoms after fighting in the Bosnian war for 15 months. He reported witnessing the loss of his family members and other relatives He was treated with venlafaxine XR 225 mg po q daily and olanzapine 10 mg po q daily without any relieve of his nightmares. He was later started on clonidine 0.1 mg po qhs. Within 2 weeks of starting clonidine, he reported improvement in the severity and duration of his nightmares and improved quality of his sleep. Clonidine a centrally acting alpha-agonist agent used to treat hypertension stimulates alpha-adrenoreceptors in the brainstem. This action results in reduced sympathetic outflow from the central nervous system. We hypothesize that this central mechanism of action is why clonidine may be more effective in treating nightmares in PTSD. Although, clonidine should be considered as an alternative in the treatment of nightmares among patients with PTSD, more clinical studies are needed to determine when to use clonidine.

Type
Abstract
Copyright
Copyright © European Psychiatric Association 2012
Submit a response

Comments

No Comments have been published for this article.